X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abiraterone acetate (1127) 1127
index medicus (1024) 1024
humans (1010) 1010
prostate cancer (973) 973
male (961) 961
oncology (701) 701
abiraterone (537) 537
enzalutamide (480) 480
docetaxel (471) 471
chemotherapy (466) 466
prostatic neoplasms, castration-resistant - drug therapy (462) 462
urology & nephrology (393) 393
metastasis (387) 387
increased survival (343) 343
cancer (341) 341
care and treatment (310) 310
antineoplastic agents - therapeutic use (290) 290
aged (286) 286
prostatic neoplasms - drug therapy (285) 285
antitumor-activity (281) 281
treatment outcome (279) 279
double-blind (277) 277
prostatic neoplasms, castration-resistant - pathology (276) 276
survival (276) 276
androgen receptor (272) 272
castration-resistant prostate cancer (254) 254
middle aged (246) 246
castration (232) 232
androgens (231) 231
men (217) 217
prednisone (216) 216
phenylthiohydantoin - analogs & derivatives (212) 212
prostatic neoplasms - pathology (180) 180
aged, 80 and over (178) 178
androgen antagonists - therapeutic use (175) 175
neoplasm metastasis (173) 173
mitoxantrone plus prednisone (170) 170
research (168) 168
therapy (167) 167
urology (167) 167
cabazitaxel (164) 164
survival analysis (164) 164
pharmacology & pharmacy (163) 163
article (160) 160
mitoxantrone (158) 158
prostate (156) 156
taxoids - therapeutic use (154) 154
drug therapy (148) 148
plus prednisone (147) 147
disease-free survival (146) 146
phenylthiohydantoin - therapeutic use (146) 146
receptors, androgen - metabolism (145) 145
disease progression (141) 141
antineoplastic combined chemotherapy protocols - therapeutic use (139) 139
cancer therapies (139) 139
analysis (137) 137
animals (134) 134
orchiectomy (126) 126
metastatic castration-resistant prostate cancer (121) 121
development and progression (120) 120
sipuleucel-t (120) 120
cyp17 (119) 119
metastases (119) 119
testosterone (119) 119
patients (118) 118
prognosis (118) 118
health aspects (116) 116
resistant prostate-cancer (116) 116
retrospective studies (116) 116
prostate-specific antigen - blood (108) 108
prostatic neoplasms - metabolism (107) 107
drug resistance, neoplasm (106) 106
medicine & public health (106) 106
endocrinology & metabolism (104) 104
i clinical-trial (104) 104
open-label (103) 103
androgen-deprivation therapy (102) 102
progression (102) 102
steroid 17-alpha-hydroxylase - antagonists & inhibitors (102) 102
trial (102) 102
androgen deprivation therapy (101) 101
prostatic neoplasms, castration-resistant - mortality (100) 100
antineoplastic agents, hormonal - therapeutic use (99) 99
immunotherapy (99) 99
urologic and male genital diseases (99) 99
abiraterone acetate - therapeutic use (98) 98
hematology, oncology and palliative medicine (96) 96
prostatic neoplasms, castration-resistant - blood (96) 96
androstenes (95) 95
clinical trials (95) 95
expression (88) 88
phase-ii (86) 86
clinical trials as topic (84) 84
review (84) 84
acetate (83) 83
placebo-controlled phase-3 (83) 83
inhibitor (82) 82
prostatic neoplasms - therapy (82) 82
receptors, androgen - genetics (82) 82
clinical-trials (81) 81
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1502) 1502
French (54) 54
German (47) 47
Spanish (19) 19
Russian (11) 11
Japanese (4) 4
Italian (2) 2
Chinese (1) 1
Czech (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 5, pp. 1277 - 1284
Journal Article
Journal Article
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
Cancer, ISSN 0008-543X, 03/2018, Volume 124, Issue 6, pp. 1216 - 1224
In this first report on RNA sequencing of prostate cancer circulating tumor cells obtained from sequential samples of patients at the start of treatment with... 
RNA sequencing | androgen receptor | targeted therapies | circulating tumor cells | AR-V7 | CYCLIN D1 | ANDROGEN-DEPRIVATION THERAPY | CIRCULATING TUMOR-CELLS | ONCOLOGY | RNA-SEQ | MEN | CARCINOMA | EXPRESSION | PROGRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Cyclin D1 - metabolism | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Neoplastic Cells, Circulating - metabolism | Male | Smad3 Protein - metabolism | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Abiraterone Acetate - pharmacology | Aged, 80 and over | Biomarkers, Tumor - metabolism | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms, Castration-Resistant - blood | Androgen Antagonists - pharmacology | Abiraterone Acetate - therapeutic use | Cyclin-Dependent Kinase 6 - metabolism | Prostatic Neoplasms, Castration-Resistant - drug therapy | Cyclin-Dependent Kinase 4 - metabolism | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Androgen Antagonists - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Phenotype | Research | Drug therapy | Prostate cancer | Smad protein | Epithelial cells | Transforming growth factor | Medical services | Smad3 protein | Cyclin D1 | Kinases | CD45 antigen | Metastases | Cell adhesion molecules | Cell adhesion & migration | Gene sequencing | Signal transduction | Transfection | Castration | Cell adhesion | Tumor cells | Medical treatment | Prednisone | Gene expression | Ribonucleic acid--RNA | Patients | Signaling | Mutation | Acetic acid | Prostate | Cancer
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 4, pp. 795 - 802
Journal Article
Journal Article
Journal Article
Journal Article